RE:RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA ResubmissionI thought a few might announce this was their last year - they expanded it a year ago and I figured they transfer some of those responsibilities and then retire a few. Very hard to tell from the outside, but a few seem to have passed the agreed upon "expire date" they used to have. So you'd think they'd try to lower costs since they are getting to breakeven. They didn't.
I think that is a mistake and a bad message. Skill duplication or questionable skill for the task is too expensive at this point given 2022 science developments did not lead to an ability to add any pipeline value or raise capital. The positive sales momentum is great, but I'd put that to the CCO/CEO roles and their strategites there gaining traction and extending usage. I did see they completely changed the comp committee so the old group has ceded way to new comers for next year. Some of the Board adds appear good on paper. But not much to show unfortunately. Let's see the numbers but there were a few last year that garnered a substantially lower vote total and I would think you'll see that message being sent even more strongly. They really should have taken last year's vote as an indication of what skills and type of people shareholders think they need and do not need. They are still way to tilted to locals versus getting more independent, objective industry experts in there. Arena's a good step, but they need 3 others outside of the Montreal mafia. They are being way to parochial and have to think had they had some "global" strategists in there some decisions may have been quite different. I hope they take this years voting in to consideration as they didn't with last years.